A widely prescribed blood pressure medication has been recalled across the United States after concerns emerged that some capsules could contain metal fragments. The discovery has prompted an urgent warning for patients to check their medicine supplies.
US-based Breckenridge Pharmaceutical announced the voluntary recall on November 16, 2026. The company identified a potential contamination risk involving one batch of Propranolol Hydrochloride Extended-Release Capsules, 60 mg.
The medication is commonly used to treat high blood pressure and certain heart conditions. It belongs to a group of medicines known as beta-blockers, which help lower blood pressure and heart rate.
According to the company’s official announcement, the affected capsules were manufactured by Adare Pharma Solutions.
The recall follows the discovery of metal contamination in a separate batch that never reached the market. The recalled batch shared an intermediate manufacturing material suspected of causing the contamination.
The company warned that swallowing contaminated capsules could cause injuries to sensitive tissues inside the body. Metal fragments could potentially damage the mouth, esophagus, stomach or intestines.
However, Breckenridge confirmed that it had not received any reports of adverse health events linked to the recalled batch when it issued the announcement.
The affected medicine was distributed to wholesalers and pharmacies across the United States between October 26 and November 4, 2026.
The recall covers only one specific batch of the medication, rather than every propranolol product available in pharmacies.
The affected product comes in bottles containing 100 capsules. Its National Drug Code is 51991-817-01, while the recalled lot number is PK25110035.
The expiration date printed on the affected bottles is May 2029. Patients should check these details carefully to determine whether their medication belongs to the recalled batch.
Breckenridge has advised patients with the recalled capsules to contact their healthcare provider immediately for medical guidance and replacement instructions.
Patients should not simply stop long-term propranolol treatment without arranging medical advice, as suddenly stopping this medicine can cause serious cardiovascular problems. They should avoid using capsules from the affected batch and arrange a safe alternative with their doctor.
The company has also instructed customers to return unused recalled capsules to the pharmacy where they obtained them.
Pharmacies, wholesalers and other distributors must identify affected stock, isolate the recalled products and prevent further distribution.
The recall is taking place with the knowledge of the US Food and Drug Administration.
The announcement comes amid broader concerns about medicine quality and manufacturing safety. Pharmaceutical companies must maintain strict production standards to prevent contamination and protect patients.
Although the recall is nationwide in the United States, there is no confirmed indication that the affected batch was distributed in Pakistan.
For patients taking propranolol, the most important precaution is to verify the manufacturer, strength and batch number before assuming their medicine is affected.
The incident raises fresh questions about pharmaceutical quality controls and how potentially contaminated medicines can be prevented from reaching patients.
